Polimorfismos genéticos asociados a toxicidad en el tratamiento con 5-fluorouracilo en pacientes con cáncer colorrectal

Introduction: Colorectal cancer is the most common malignancy of digestive tract. The treatment based basically on administering antitumor medications, like 5-fluorouracil (5-FU), which belongs to antimetabolites, antineoplastic agents. However, it has been shown that there toxicity related genetic polymorphism in patients treated with 5-FU, including gastrointestinal symptoms, myelosuppression, and neurotoxicity. variations four genes have studied, ABCB1, DPYD, MTHFR, TYMS. Methodology: Bibliographic review digital articles, starting research information about as colorectal cancer, its adverse reactions, polymorphisms, toxicity. database used PubMed, ScienceDirect, Scielo, published within last ten years. It included scientific articles studies older than 18. Publications Spanish English well full-text articles. Additionally, polymorphisms were analyzed NCBI (National Center for Biotechnology Information) database, from allelic frequencies at global Latin American levels obtained. Results: A total 11 reviewed, where we obtained data developed who receive 5-fluorouracil. are was established trigger manifests different forms: diarrhea, stomatitis, mucositis, neutropenia.